Stammdaten
Unternehmen
| Name | Enliven Therapeutics, Inc. |
|---|---|
| Ticker | ELVN |
| CIK | 0001672619 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | Enliven Therapeutics, Inc. |
Status
| Zuletzt geprüft | 2026-03-20 22:35:55.749874 |
|---|
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5,000 | 27.76 | -138,800.00 | -54,3% | |
| 2026-03-10 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -10,129 | 30.19 | -305,826.92 | -119,5% | |
| 2026-03-10 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -10,129 | 30.19 | -305,826.92 | -119,5% | |
| 2026-03-09 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -29,871 | 30.02 | -896,811.06 | -350,5% | |
| 2026-03-09 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -29,871 | 30.02 | -896,811.06 | -350,5% | |
| 2026-03-06 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -10,000 | 29.58 | -295,839.00 | -115,6% | |
| 2026-02-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -45,000 | 26.17 | -1,177,861.50 | -460,4% | |
| 2026-02-17 | Heyman Richard A. | Director | Open Market Sale | -1,230 | 26.18 | -32,196.36 | -12,6% | |
| 2026-02-17 | Heyman Richard A. | Director | Open Market Sale | -1,230 | 26.18 | -32,196.36 | -12,6% | |
| 2026-02-17 | Heyman Richard A. | Director | Open Market Sale | -1,230 | 26.18 | -32,196.36 | -12,6% | |
| 2026-02-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -45,000 | 26.17 | -1,177,861.50 | -460,4% | |
| 2026-02-06 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5,000 | 29.04 | -145,219.00 | -56,8% | |
| 2026-01-20 | Heyman Richard A. | Director | Open Market Sale | -718 | 26.96 | -19,354.41 | -7,6% | |
| 2026-01-20 | Heyman Richard A. | Director | Open Market Sale | -512 | 26.46 | -13,547.11 | -5,3% | |
| 2026-01-20 | Heyman Richard A. | Director | Open Market Sale | -718 | 26.96 | -19,354.41 | -7,6% | |
| 2026-01-20 | Heyman Richard A. | Director | Open Market Sale | -512 | 26.46 | -13,547.11 | -5,3% | |
| 2026-01-20 | Heyman Richard A. | Director | Open Market Sale | -512 | 26.46 | -13,547.11 | -5,3% | |
| 2026-01-20 | Heyman Richard A. | Director | Open Market Sale | -718 | 26.96 | -19,354.41 | -7,6% | |
| 2026-01-20 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5,491 | 26.37 | -144,814.14 | -56,6% | |
| 2026-01-20 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -14,509 | 26.90 | -390,284.85 | -152,5% | |
| 2026-01-09 | Heyman Richard A. | Director | Open Market Sale | -4,285 | 25.00 | -107,125.43 | -41,9% | |
| 2026-01-09 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -48,057 | 27.98 | -1,344,836.70 | -525,6% | |
| 2026-01-09 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -243 | 28.50 | -6,925.50 | -2,7% | |
| 2026-01-09 | Heyman Richard A. | Director | Open Market Sale | -4,285 | 25.00 | -107,125.43 | -41,9% | |
| 2026-01-09 | Heyman Richard A. | Director | Open Market Sale | -4,285 | 25.00 | -107,125.43 | -41,9% | |
| 2026-01-09 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -41,198 | 24.90 | -1,025,863.16 | -401,0% | |
| 2026-01-09 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -50,000 | 29.13 | -1,456,715.00 | -569,4% | |
| 2026-01-08 | Heyman Richard A. | Director | Open Market Sale | -1,620 | 25.00 | -40,500.00 | -15,8% | |
| 2026-01-08 | Heyman Richard A. | Director | Open Market Sale | -8,015 | 25.04 | -200,655.53 | -78,4% | |
| 2026-01-08 | Heyman Richard A. | Director | Open Market Sale | -1,620 | 25.00 | -40,500.00 | -15,8% | |
| 2026-01-08 | Heyman Richard A. | Director | Open Market Sale | -8,015 | 25.04 | -200,655.53 | -78,4% | |
| 2026-01-08 | Heyman Richard A. | Director | Open Market Sale | -1,620 | 25.00 | -40,500.00 | -15,8% | |
| 2026-01-08 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -7,500 | 20.13 | -150,961.50 | -59,0% | |
| 2026-01-08 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -33,802 | 24.92 | -842,474.29 | -329,3% | |
| 2026-01-08 | Heyman Richard A. | Director | Open Market Sale | -8,015 | 25.04 | -200,655.53 | -78,4% | |
| 2025-12-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5,000 | 16.84 | -84,206.00 | -32,9% | |
| 2025-12-08 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -1,705 | 21.78 | -37,133.88 | -14,5% | |
| 2025-12-08 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -4,958 | 20.76 | -102,938.99 | -40,2% | |
| 2025-11-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -492 | 23.09 | -11,360.77 | -4,4% | |
| 2025-11-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -12,008 | 22.30 | -267,794.01 | -104,7% | |
| 2025-11-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -12,500 | 21.82 | -272,738.75 | -106,6% | |
| 2025-11-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -613 | 17.94 | -10,995.44 | -4,3% | |
| 2025-11-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -6,054 | 17.35 | -105,038.72 | -41,1% | |
| 2025-10-20 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -12,500 | 22.08 | -276,025.00 | -107,9% | |
| 2025-10-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -12,500 | 21.33 | -266,653.75 | -104,2% | |
| 2025-10-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -6,667 | 20.10 | -133,992.70 | -52,4% | |
| 2025-09-29 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3,250 | 20.40 | -66,291.23 | -25,9% | |
| 2025-09-26 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -3,700 | 20.06 | -74,227.55 | -29,0% | |
| 2025-09-26 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -4,000 | 20.25 | -81,005.20 | -31,7% | |
| 2025-09-23 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -2,800 | 20.03 | -56,084.00 | -21,9% | |
| 2025-09-23 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -1,500 | 20.03 | -30,045.00 | -11,7% | |
| 2025-09-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -4,870 | 19.11 | -93,063.27 | -36,4% | |
| 2025-09-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -2,130 | 20.02 | -42,634.08 | -16,7% | |
| 2025-09-19 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -1,000 | 20.25 | -20,250.00 | -7,9% | |
| 2025-09-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -5,000 | 19.09 | -95,473.00 | -37,3% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.